Singular Genomics Systems, Inc. Common Stock
OMIC US82933R3084
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -55% | -83% | -78% | 34% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Spaventa Andrew CEO |
19.89 USD |
800 Sold |
15,912 USD |
12/02/2025 | 14/02/2025 |
| Spaventa Andrew CEO |
20.16 USD |
180 Sold |
3,629 USD |
15/12/2024 | 16/12/2024 |
| Spaventa Andrew CEO |
22.55 USD |
695 Sold |
15,669 USD |
12/11/2024 | 12/11/2024 |
| Spaventa Andrew CEO |
12.38 USD |
175 Sold |
2,167 USD |
15/09/2024 | 15/09/2024 |
| Spaventa Andrew CEO |
0.42 USD |
75,000 Bought |
31,755 USD |
16/11/2023 | 17/11/2023 |
| Spaventa Andrew CEO |
0.41 USD |
43,468 Bought |
17,857 USD |
16/11/2023 | 16/11/2023 |
| Glezer Eli N. CSO |
0.43 USD |
200,000 Bought |
85,640 USD |
16/11/2023 | 16/11/2023 |